Decreased_VBN levels_NNS of_IN dehydroepiandrosterone_NN sulphate_NN in_IN severe_JJ critical_JJ illness_NN :_: a_DT sign_NN of_IN exhausted_VBN adrenal_JJ reserve_NN ?_SENT Abstract_NN |_SYM Introduction_NP |_SYM Dehydroepiandrosterone_NP (_( DHEA_NP )_) and_CC its_PP$ sulphate_NN (_( DHEAS_NP )_) are_VBP pleiotropic_JJ adrenal_JJ hormones_NNS with_IN immunostimulating_VBG and_CC antiglucocorticoid_JJ effects_NNS ._SENT The_DT present_JJ study_NN was_VBD conducted_VBN to_TO evaluate_VB the_DT time_NN course_NN of_IN DHEAS_NP levels_NNS in_IN critically_RB ill_JJ patients_NNS and_CC to_TO study_VB their_PP$ association_NN with_IN the_DT hypothalamic_JJ --_: pituitary_NN --_: adrenal_JJ axis_NN ._SENT Materials_NNS and_CC method_NN |_SYM This_DT was_VBD a_DT prospective_JJ observational_JJ clinical_JJ and_CC laboratory_NN study_NN ,_, including_VBG 30_CD patients_NNS with_IN septic_JJ shock_NN ,_, eight_CD patients_NNS with_IN multiple_JJ trauma_NN ,_, and_CC 40_CD age-_NN and_CC sex-matched_JJ control_NN patients_NNS ._SENT We_PP took_VBD serial_JJ measurements_NNS of_IN blood_NN concentrations_NNS of_IN DHEAS_NP ,_, cortisol_NN ,_, tumour_NN necrosis_NN factor-alpha_NP and_CC IL-6_NP ,_, and_CC of_IN adrenocorticotrophic_JJ hormone_NN immunoreactivity_NN over_IN 14_CD days_NNS or_CC until_IN discharge/death_NN ._SENT Results_NNS |_SYM On_IN admission_NN ,_, DHEAS_NP was_VBD extremely_RB low_JJ in_IN septic_JJ shock_NN (_( 1.2_CD +-_NN 0.8_CD mol/l_NN )_) in_IN comparison_NN with_IN multiple_JJ trauma_NN patients_NNS (_( 2.4_CD +-_NN 0.5_CD mumol/l_NN ;_: P_NN <_SYM 0.05_CD )_) and_CC control_NN patients_NNS (_( 4.2_CD +-_NN 1.8_CD ;_: P_NN <_SYM 0.01_CD )_) ._SENT DHEAS_NP had_VBD a_DT significant_JJ (_( P_NN <_SYM 0.01_CD )_) negative_JJ correlation_NN with_IN age_NN ,_, IL-6_NP and_CC Acute_NP Physiology_NP and_CC Chronic_NP Health_NP Evaluation_NP II_NP scores_NNS in_IN both_DT patient_JJ groups_NNS ._SENT Only_RB during_IN the_DT acute_JJ phase_NN did_VBD DHEAS_NP negatively_RB correlate_VBP with_IN dopamine_NN ._SENT Nonsurvivors_NNS of_IN septic_JJ shock_NN (_( n_NN =_SYM 11_CD )_) had_VBD lower_JJR DHEAS_NP levels_NNS (_( 0.4_CD +-_NN 0.3_CD mumol/l_NN )_) than_IN did_VBD survivors_NNS (_( 1.7_CD +-_NN 1.1_CD mumol/l_NN ;_: P_NN <_SYM 0.01_CD )_) ._SENT The_DT time_NN course_NN of_IN DHEAS_NP exhibited_VBD a_DT persistent_JJ depletion_NN during_IN follow_VB up_RP ,_, whereas_IN cortisol_NN levels_NNS were_VBD increased_VBN at_IN all_DT time_NN points_NNS ._SENT Conclusion_NN |_SYM We_PP identified_VBD extremely_RB low_JJ DHEAS_NP levels_NNS in_IN septic_JJ shock_NN and_CC ,_, to_TO a_DT lesser_JJR degree_NN ,_, in_IN multiple_JJ trauma_NN patients_NNS as_RB compared_VBN with_IN those_DT of_IN age-_NN and_CC sex-matched_JJ control_NN patients_NNS ._SENT There_RB appeared_VBD to_TO be_VB a_DT dissociation_NN between_IN DHEAS_NP (_( decreased_VBN )_) and_CC cortisol_NN (_( increased_VBN )_) levels_NNS ,_, which_WDT changed_VBD only_RB slightly_RB over_IN time_NN ._SENT Nonsurvivors_NNS of_IN sepsis_NN and_CC patients_NNS with_IN relative_JJ adrenal_JJ insufficiency_NN had_VBD the_DT lowest_JJS DHEAS_NP values_NNS ,_, suggesting_VBG that_IN DHEAS_NP might_MD be_VB a_DT prognostic_JJ marker_NN and_CC a_DT sign_NN of_IN exhausted_VBN adrenal_JJ reserve_NN in_IN critical_JJ illness_NN ._SENT adrenal_JJ insufficiency_NN ,_, dehydroepiandrosterone_NN sulphate_NN ,_, multiple_JJ trauma_NN ,_, hypothalamic_JJ --_: pituitary_NN --_: adrenal_JJ axis_NN ,_, sepsis_NN ,_, -pituitary_NN --_: adrenal_JJ axis_NN ,_, sepsis_NN ,_, Introduction_NP :_: Dehydroepiandrosterone_NP (_( DHEA_NP )_) and_CC its_PP$ sulphate_NN (_( DHEAS_NP )_) are_VBP the_DT most_RBS abundant_JJ steroids_NNS secreted_VBN by_IN the_DT adrenal_JJ cortex_NN ._SENT The_DT concentration_NN of_IN DHEA_NP in_IN the_DT blood_NN oscillates_VBZ in_IN parallel_NN with_IN cortisol_NN ,_, in_IN response_NN to_TO levels_NNS of_IN adrenocorticotrophic_JJ hormone_NN (_( ACTH_NP )_) ,_, but_CC without_IN feedback_NN control_NN at_IN the_DT hypothalamic_JJ --_: pituitary_JJ level_NN ._SENT The_DT physiological_JJ role_NN and_CC biological_JJ actions_NNS of_IN DHEA(S)_NP are_VBP not_RB well_RB known_VBN but_CC studies_NNS in_IN humans_NNS suggest_VBP a_DT positive_JJ impact_NN on_IN sense_NN of_IN well-being_NN ,_, and_CC DHEA_NP has_VBZ recently_RB been_VBN recognized_VBN as_IN a_DT potent_JJ modulator_NN of_IN the_DT immune_JJ response_NN ._SENT DHEA_NP improved_VBD host_NN defences_NNS by_IN restoring_VBG immune_JJ cell_NN function_NN and_CC reversed_JJ susceptibility_NN to_TO infection_NN ._SENT Serum_NP DHEA(S)_NP concentration_NN was_VBD low_JJ in_IN patients_NNS with_IN primary_JJ adrenal_JJ insufficiency_NN ,_, and_CC short-term_JJ oral_JJ DHEA_NP replacement_NN improved_VBD the_DT clinical_JJ condition_NN of_IN these_DT patients_NNS ._SENT Functional_JJ or_CC relative_JJ adrenal_JJ insufficiency_NN frequently_RB occurs_VBZ in_IN critically_RB ill_JJ patients_NNS ,_, with_IN possible_JJ fatal_JJ consequences_NNS ,_, although_IN diagnostic_JJ criteria_NNS for_IN this_DT entity_NN still_RB pose_VB problems_NNS ._SENT We_PP hypothesize_VBP that_IN the_DT serum_NN DHEAS_NP level_NN has_VBZ utility_NN as_IN a_DT diagnostic_JJ tool_NN and_CC a_DT prognostic_JJ marker_NN in_IN such_JJ patients_NNS ._SENT Furthermore_RB ,_, low_JJ serum_NN concentrations_NNS of_IN DHEAS_NP might_MD be_VB a_DT more_RBR sensitive_JJ marker_NN of_IN hypothalamic_JJ --_: pituitary_NN --_: adrenal_JJ (_( HPA_NP )_) hypofunction_NN than_IN is_VBZ glucocorticoid_JJ secretion_NN ._SENT The_DT present_JJ study_NN was_VBD conducted_VBN to_TO evaluate_VB the_DT time_NN course_NN of_IN DHEAS_NP levels_NNS (_( an_DT immunostimulator_NN )_) as_IN compared_VBN with_IN those_DT of_IN cortisol_NN (_( an_DT immunosuppressor_NN )_) ,_, ACTH_NP (_( an_DT inducer_NN of_IN DHEAS_NP )_) and_CC cytokines_NNS (_( stimulators_NNS of_IN the_DT HPA_NP axis_NN )_) in_IN patients_NNS with_IN critical_JJ illness_NN and_CC in_IN age-_NN and_CC sex-matched_JJ control_NN patients_NNS ._SENT Study_NN design_NN |_SYM This_DT was_VBD a_DT prospective_JJ ,_, observational_JJ ,_, clinical_JJ and_CC laboratory_NN study_NN conducted_VBN in_IN a_DT 20-bed_JJ medical/surgical/neurosurgical_JJ intensive_JJ care_NN unit_NN ._SENT Patients_NPS |_SYM Approval_NN for_IN the_DT study_NN was_VBD obtained_VBN from_IN our_PP$ institutional_JJ Human_NP Subjects_NP Research_NP Committee_NP ,_, and_CC written_JJ informed_JJ consent_NN from_IN first-degree_NN relatives_NNS was_VBD mandatory_JJ ._SENT Thirty-eight_JJ consecutive_JJ patients_NNS who_WP were_VBD admitted_VBN to_TO the_DT intensive_JJ care_NN unit_NN with_IN septic_JJ shock_NN (_( n_NN =_SYM 30_CD )_) or_CC severe_JJ multiple_JJ trauma_NN (_( Injury_NP Severity_NP Score_NN >20_NN ;_: n_NN =_SYM 8_CD )_) were_VBD included_VBN in_IN the_DT study_NN within_IN 6_CD hours_NNS after_IN admission_NN ._SENT Exclusion_NN criteria_NNS were_VBD as_RB follows_VBZ :_: age_NN under_IN 18_CD years_NNS ;_: use_VB of_IN corticosteroids_NNS ,_, DHEA_NP or_CC other_JJ drugs_NNS that_WDT affect_VBP the_DT HPA_NP axis_NN ;_: pre-existing_VBG adrenal_JJ insufficiency_NN or_CC known_VBN abnormalities_NNS of_IN the_DT HPA_NP axis_NN ;_: and_CC presence_NN of_IN diabetes_NN mellitus_NN or_CC congestive_JJ heart_NN failure_NN ._SENT Age-_NP and_CC sex-matched_JJ control_NN patients_NNS (_( n_NN =_SYM 40_CD )_) were_VBD patients_NNS without_IN acute_JJ medical_JJ illness_NN who_WP were_VBD admitted_VBN to_TO the_DT medical_JJ department_NN for_IN routine_JJ diagnosis_NN and_CC treatment_NN ._SENT Data_NNS collection_NN |_SYM In_IN patients_NNS with_IN septic_JJ shock_NN or_CC multiple_JJ trauma_NN ,_, Acute_NP Physiology_NP and_CC Chronic_NP Health_NP Evaluation_NP (_( APACHE_NP )_) II_NP and_CC Sequential_NP Organ_NP Failure_NN Assessment_NP scores_NNS ,_, and_CC intensive_JJ care_NN unit_NN mortality_NN were_VBD used_VBN to_TO assess_VB the_DT severity_NN of_IN disease_NN ._SENT In_IN addition_NN ,_, use_NN of_IN dopamine_NN (_( cumulative_JJ dose_NN in_IN milligrams_NNS per_IN day_NN )_) was_VBD recorded_VBN ._SENT We_PP obtained_VBD serial_JJ blood_NN samples_NNS for_IN measurement_NN of_IN serum_NN cortisol_NN and_CC DHEAS_NP ,_, and_CC plasma_NN ACTH_NP ,_, IL-6_NP and_CC tumour_NN necrosis_NN factor_NN (TNF)-alpha_NN once_IN a_DT day_NN between_IN 0700_CD and_CC 0800_CD h._NP Follow_NP up_RB was_VBD conducted_VBN for_IN 14_CD days_NNS ,_, or_CC until_IN death_NN or_CC discharge_NN from_IN the_DT intensive_JJ care_NN unit_NN ._SENT Blood_NN samples_NNS were_VBD stored_VBN at_IN -70C_NN until_IN use_NN ._SENT Immunoreactive_NP DHEAS_NP ,_, cortisol_NN ,_, ACTH_NP ,_, TNF-alpha_NP and_CC IL-6_NP concentrations_NNS were_VBD measured_VBN using_VBG commercially_RB available_JJ chemiluminescent_JJ enzyme_NN immunoassays_NNS with_IN the_DT Immulite_NN Automated_VBN Immunoassay_NP System_NP (_( Diagnostic_NP Products_NPS Corp_NP ,_, Los_NP Angeles_NP ,_, CA_NP ,_, USA_NP )_) ._SENT In_IN patients_NNS with_IN clinical_JJ suspicion_NN of_IN (_( relative_JJ )_) adrenal_JJ insufficiency_NN (_( unexplained_JJ hypotension_NN and_CC resistance_NN to_TO inappropriately_RB high_JJ doses_NNS of_IN vasoactive_JJ drugs_NNS )_) a_DT low-dose_NN ACTH_NP (_( 1_CD mug_NN )_) stimulation_NN test_NN was_VBD performed_VBN ._SENT A_DT normal_JJ cortisol_NN response_NN was_VBD defined_VBN as_IN greater_JJR than_IN 550_CD nmol/l_NN after_IN stimulation_NN and_CC an_DT increase_NN of_IN 150_CD nmol/l_NN or_CC more_JJR ._SENT Statistical_JJ analysis_NN |_SYM Values_NP are_VBP expressed_VBN as_IN means_NN +-_NN SD_NN ._SENT Qualitative_JJ data_NNS were_VBD analysed_VBN using_VBG the_DT chi2_JJ test_NN ._SENT Groups_NNS were_VBD compared_VBN using_VBG the_DT Kruskal-Wallis_NP test_NN ,_, with_IN Dunn_NP 's_POS test_NN for_IN multiple_JJ comparisons_NNS ._SENT The_DT Spearman_NP rank_NN order_NN correlation_NN coefficient_NN (_( rs_NNS )_) was_VBD used_VBN to_TO evaluate_VB relations_NNS for_IN individual_JJ data_NNS ._SENT P_NN <_SYM 0.05_CD was_VBD considered_VBN statistically_RB significant_JJ ._SENT All_DT analyses_NNS were_VBD performed_VBN using_VBG a_DT statistical_JJ software_NN package_NN (_( SPSS_NP 9.0.1_CD ;_: SPSS_NP Inc_NP ,_, Chicago_NP ,_, IL_NP ,_, USA_NP )_) ._SENT The_DT clinical_JJ and_CC laboratory_NN characteristics_NNS of_IN the_DT patients_NNS and_CC control_NN groups_NNS on_IN admission_NN are_VBP summarized_VBN in_IN Table_NP ._SENT On_IN admission_NN ,_, patients_NNS with_IN septic_JJ shock_NN had_VBD significantly_RB lower_JJR DHEAS_NP levels_NNS (_( 1.2_CD +-_NN 0.8_CD mol/l_NN )_) than_IN did_VBD those_DT with_IN multiple_JJ trauma_NN (_( 2.4_CD +-_NN 0.5_CD mol/l_NN ,_, P_NN <_SYM 0.05_CD )_) and_CC control_NN patients_NNS (_( 4.2_CD +-_NN 1.8_CD mumol/l_NN ,_, P_NN <_SYM 0.01_CD )_) ._SENT There_EX was_VBD a_DT significant_JJ negative_JJ correlation_NN between_IN DHEAS_NP and_CC age_NN (_( rs_NNS =_SYM -0.55_CD ,_, P_NN <_SYM 0.01_CD )_) in_IN the_DT patient_JJ groups_NNS (_( pooled_VBN )_) ,_, but_CC there_EX was_VBD no_DT significant_JJ difference_NN in_IN DHEAS_NP concentrations_NNS between_IN male_JJ and_CC female_JJ patients_NNS ._SENT We_PP found_VBD a_DT negative_JJ correlation_NN between_IN DHEAS_NP and_CC dopamine_NN only_RB during_IN the_DT acute_JJ phase_NN (_( septic_JJ shock_NN :_: rs_NNS =_SYM -0.60_CD ;_: trauma_NN :_: rs_NNS =_SYM -0.55_CD ;_: P_NN <_SYM 0.01_CD )_) ._SENT Also_RB ,_, the_DT correlation_NN between_IN DHEAS_NP and_CC IL-6_NP (_( septic_JJ shock_NN :_: rs_NNS =_SYM -0.61_CD ,_, P_NN <_SYM 0.01_CD ;_: trauma_NN :_: rs_NNS =_SYM 0.47_CD ,_, P_NN <_SYM 0.05_CD )_) was_VBD more_RBR pronounced_VBN during_IN the_DT acute_JJ phase_NN ._SENT These_DT correlations_NNS were_VBD lost_VBN during_IN prolonged_JJ illness_NN (_( after_IN 5_CD days_NNS )_) ._SENT Table_NP 1_CD |_SYM Clinical_JJ and_CC laboratory_NN data_NNS on_IN admission_NN in_IN patients_NNS with_IN septic_JJ shock_NN or_CC multiple_JJ trauma_NN ,_, and_CC age-_NN and_CC sex-matched_JJ control_NN patients_NNS The_DT time_NN course_NN of_IN DHEAS_NP during_IN the_DT observation_NN period_NN of_IN 14_CD days_NNS is_VBZ shown_VBN in_IN Fig._NN ._SENT In_IN both_DT septic_JJ and_CC trauma_NN patients_NNS ,_, DHEAS_NP concentrations_NNS were_VBD consistently_RB lower_JJR than_IN those_DT in_IN control_NN patients_NNS over_IN time_NN ._SENT In_IN contrast_NN ,_, cortisol_NN levels_NNS were_VBD persistently_RB elevated_VBN at_IN all_DT time_NN points_NNS ,_, in_IN both_DT septic_JJ and_CC trauma_NN patients_NNS ._SENT On_IN admission_NN ,_, nonsurvivors_NNS of_IN septic_JJ shock_NN (_( n_NN =_SYM 11_CD )_) had_VBD lower_JJR DHEAS_NP levels_NNS (_( 0.4_CD +-_NN 0.3_CD mol/l_NN )_) than_IN did_VBD survivors_NNS (_( 1.7_CD +-_NN 1.1_CD mol/l_NN ,_, P_NN <_SYM 0.01_CD )_) ._SENT In_IN addition_NN ,_, DHEAS_NP was_VBD inversely_RB correlated_VBN with_IN APACHE_NP II_NP (_( rs_NN =_SYM -0.52_CD ,_, P_NN <_SYM 0.01_CD )_) and_CC Sequential_NP Organ_NP Failure_NN Assessment_NP (_( rs_NN =_SYM -0.45_CD ,_, P_NN <_SYM 0.05_CD )_) scores_NNS ._SENT Figure_NP 1_CD |_SYM The_DT time_NN course_NN of_IN serum_NN dehydroepiandrosterone_NN sulphate_NN (_( DHEAS_NP )_) levels_NNS in_IN patients_NNS with_IN septic_JJ shock_NN ,_, patients_NNS with_IN multiple_JJ trauma_NN ,_, and_CC age-_NN and_CC sex-matched_JJ control_NN patients_NNS ._SENT The_DT time_NN course_NN of_IN serum_NN dehydroepiandrosterone_NN sulphate_NN (_( DHEAS_NP )_) levels_NNS in_IN patients_NNS with_IN septic_JJ shock_NN ,_, patients_NNS with_IN multiple_JJ trauma_NN ,_, and_CC age-_NN and_CC sex-matched_JJ control_NN patients_NNS ._SENT In_IN eight_CD septic_JJ patients_NNS there_EX was_VBD clinical_JJ suspicion_NN of_IN (_( relative_JJ )_) adrenal_JJ insufficiency_NN ,_, which_WDT was_VBD confirmed_VBN by_IN a_DT blunted_VBN response_NN to_TO low-dose_NN ACTH_NP in_IN four_CD cases_NNS ._SENT The_DT patients_NNS with_IN adrenal_JJ insufficiency_NN had_VBD lower_JJR DHEAS_NP levels_NNS at_IN the_DT time_NN of_IN testing_NN (_( 0.35_CD +-_NN 0.3_CD mol/l_NN )_) than_IN did_VBD those_DT with_IN '_'' normal_JJ '_'' adrenal_JJ function_NN (_( 1.3_CD +-_NN 0.8_CD mol/l_NN ,_, P_NN <_SYM 0.05_CD )_) ._SENT We_PP found_VBD a_DT clear_JJ dissociation_NN between_IN high_JJ blood_NN levels_NNS of_IN cortisol_NN and_CC extremely_RB low_JJ levels_NNS of_IN DHEAS_NP in_IN critically_RB ill_JJ patients_NNS in_IN both_CC the_DT acute_JJ and_CC prolonged_JJ phases_NNS ._SENT Parker_NP and_CC coworkers_NNS demonstrated_VBD such_PDT a_DT divergence_NN in_IN adrenal_JJ steroid_NN secretion_NN ;_: in_IN that_DT study_NN serum_NN cortisol_NN was_VBD increased_VBN in_IN adult_JJ men_NNS with_IN burn_NN injuries_NNS ,_, whereas_IN serum_NN DHEAS_NP was_VBD reduced_VBN ._SENT Luppa_NNS and_CC coworkers_NNS studied_VBD serum_NN androgens_NNS in_IN a_DT large_JJ group_NN of_IN critically_RB ill_JJ patients_NNS and_CC also_RB found_VBD markedly_RB decreased_VBN DHEAS_NP levels_NNS in_IN both_DT males_NNS and_CC females_NNS ,_, mainly_RB in_IN those_DT patients_NNS with_IN a_DT prolonged_JJ clinical_JJ course_NN ._SENT These_DT data_NNS indicate_VBP a_DT shift_NN in_IN adrenal_JJ steroid_NN synthesis_NN away_RB from_IN mineralocorticoids_NNS and_CC androgens_NNS and_CC toward_IN excessive_JJ cortisol_NN production_NN ._SENT The_DT dissociation_NN between_IN blood_NN levels_NNS of_IN cortisol_NN and_CC DHEAS_NP appears_VBZ to_TO be_VB a_DT contradiction_NN because_IN both_DT hormones_NNS are_VBP synthesized_VBN and_CC secreted_VBN mainly_RB by_IN the_DT adrenal_JJ cortex_NN ._SENT However_RB ,_, DHEAS_NP is_VBZ produced_VBN mainly_RB in_IN the_DT zona_NN reticularis_NN of_IN the_DT adrenal_JJ cortex_NN ,_, possibly_RB indicating_VBG that_IN a_DT differential_JJ alteration_NN in_IN the_DT cortical_JJ zone_NN is_VBZ responsible_JJ for_IN DHEAS_NP deficiency_NN during_IN severe_JJ critical_JJ illness_NN ._SENT The_DT sustained_JJ hypercortisolism_NN ,_, as_RB opposed_VBN to_TO the_DT marked_JJ DHEAS_NP depletion_NN ,_, during_IN severe_JJ critical_JJ illness_NN could_MD theoretically_RB result_VB in_IN an_DT imbalance_NN between_IN immunosuppressive_JJ and_CC immunostimulatory_JJ pathways_NNS ,_, and_CC may_MD therefore_RB play_VB a_DT role_NN in_IN susceptibility_NN to_TO infectious_JJ complications_NNS ._SENT Interestingly_RB ,_, we_PP found_VBD the_DT lowest_JJS DHEAS_NP and_CC the_DT highest_JJS cortisol_NN levels_NNS in_IN nonsurvivors_NNS and_CC the_DT most_RBS severely_RB ill_JJ patients_NNS ,_, indicating_VBG that_IN the_DT DHEAS_NP :_: cortisol_NN ratio_NN might_MD be_VB a_DT prognostic_JJ indicator_NN for_IN outcome_NN of_IN critical_JJ illness_NN ,_, in_IN particular_JJ septic_JJ shock_NN ._SENT Interpretation_NN of_IN cortisol_NN levels_NNS measured_VBN in_IN seriously_RB ill_JJ patients_NNS is_VBZ difficult_JJ ._SENT Serum_NP cortisol_NN levels_NNS that_WDT are_VBP regarded_VBN as_IN high_JJ in_IN control_NN individuals_NNS may_MD be_VB inappropriately_RB low_JJ in_IN patients_NNS who_WP are_VBP severely_RB ill_JJ ._SENT We_PP recently_RB showed_VBD that_IN functional_JJ or_CC relative_JJ adrenal_JJ insufficiency_NN can_MD be_VB present_JJ in_IN critically_RB ill_JJ patients_NNS despite_NN '_POS high_NN '_POS initial_JJ serum_NN cortisol_NN levels_NNS ._SENT By_IN using_VBG the_DT low-dose_NN ACTH_NP stimulation_NN test_NN and_CC Thorn_NP test_NN ,_, we_PP demonstrated_VBD the_DT relative_JJ lack_NN of_IN adrenocortical_JJ response_NN to_TO extra_JJ stimulation_NN by_IN ACTH_NP in_IN some_DT critically_RB ill_JJ patients_NNS ,_, because_IN their_PP$ HPA_NP axis_NN is_VBZ already_RB maximally_RB stimulated_VBN ._SENT In_IN the_DT present_JJ study_NN the_DT low-dose_NN ACTH_NP test_NN identified_VBD four_CD patients_NNS out_RB of_IN eight_CD with_IN a_DT clinical_JJ suspicion_NN for_IN relative_JJ adrenal_JJ insufficiency_NN ._SENT These_DT patients_NNS had_VBD very_RB low_JJ serum_NN concentrations_NNS of_IN DHEAS_NP ,_, which_WDT may_MD also_RB be_VB a_DT sign_NN of_IN limited_JJ adrenocortical_JJ reserve_NN arising_VBG during_IN the_DT course_NN of_IN critical_JJ illness_NN ._SENT In_IN both_DT septic_JJ and_CC trauma_NN patients_NNS we_PP found_VBD a_DT similar_JJ degree_NN of_IN stimulation_NN of_IN the_DT HPA_NP axis_NN ;_: however_RB ,_, patients_NNS with_IN septic_JJ shock_NN were_VBD more_JJR severely_RB ill_JJ than_IN were_VBD patients_NNS with_IN multiple_JJ trauma_NN ,_, as_RB reflected_VBD by_IN their_PP$ APACHE_NP II_NP scores_NNS ,_, and_CC TNF-alpha_NP and_CC IL-6_NP levels_NNS ._SENT One_PP could_MD argue_VB that_IN this_DT also_RB indicates_VBZ a_DT state_NN of_IN exhausted_VBN adrenal_JJ reserve_NN ._SENT We_PP found_VBD a_DT relation_NN between_IN dopamine_NN use_NN and_CC DHEAS_NP levels_NNS ,_, but_CC only_RB during_IN the_DT acute_JJ phase_NN ._SENT Therefore_RB ,_, acute_JJ depletion_NN of_IN DHEAS_NP might_MD reflect_VB the_DT liberal_JJ use_NN of_IN dopamine_NN ._SENT In_IN addition_NN ,_, we_PP found_VBD a_DT negative_JJ correlation_NN between_IN IL-6_NP and_CC DHEAS_NP during_IN the_DT acute_JJ phase_NN ._SENT In_IN healthy_JJ persons_NNS ,_, serum_NN IL-6_NN correlated_VBD inversely_RB with_IN DHEAS_NP ,_, and_CC DHEA_NP administration_NN led_VBD to_TO inhibition_NN of_IN IL-6_JJ secretion_NN from_IN monocytes_NNS ,_, indicating_VBG a_DT functional_JJ link_NN between_IN DHEAS_NP and_CC IL-6_NP ._SENT IL-6_NP can_MD act_VB synergistically_RB with_IN ACTH_NP on_IN the_DT adrenal_JJ glands_NNS to_TO release_VB cortisol_NN ._SENT Therefore_RB ,_, IL-6_NP may_MD be_VB an_DT important_JJ regulator_NN of_IN DHEAS_NP in_IN (_( acute_JJ )_) critical_JJ illness_NN ._SENT However_RB ,_, the_DT dopamine_NN dosage_NN and_CC IL-6_NN levels_NNS decreased_VBD significantly_RB over_IN time_NN whereas_IN DHEAS_NP concentrations_NNS remained_VBD low_JJ ,_, suggesting_VBG different_JJ mechanisms_NNS for_IN the_DT prolonged_JJ DHEAS_NP depletion_NN during_IN critical_JJ illness_NN ._SENT We_PP found_VBD a_DT negative_JJ correlation_NN between_IN age_NN and_CC DHEAS_NP concentrations_NNS ._SENT DHEAS_NP concentrations_NNS exhibit_VBP a_DT biphasic_JJ time_NN course_NN following_VBG the_DT onset_NN of_IN adrenarche_NN ,_, reaching_VBG a_DT peak_NN between_IN the_DT ages_NNS 20_CD and_CC 30_CD years_NNS ,_, and_CC with_IN the_DT greatest_JJS decline_NN occurring_VBG by_IN age_NN 50_CD --_: 60_CD years_NNS ._SENT This_DT dramatic_JJ age-related_JJ reduction_NN might_MD be_VB caused_VBN by_IN a_DT specific_JJ defect_NN in_IN the_DT desmolase_NN activity_NN in_IN the_DT reticular_JJ zone_NN of_IN the_DT adrenal_JJ gland_NN ._SENT Most_JJS of_IN patients_NNS studied_VBN here_RB ,_, including_VBG control_NN patients_NNS ,_, were_VBD aged_VBN approximately_RB 50_CD --_: 60_CD years_NNS ._SENT In_IN conclusion_NN ,_, we_PP found_VBD extremely_RB low_JJ DHEAS_NP levels_NNS in_IN virtually_RB all_DT critically_RB ill_JJ patients_NNS ,_, in_IN both_DT septic_JJ shock_NN and_CC multiple_JJ trauma_NN ._SENT DHEAS_NP depletion_NN was_VBD associated_VBN with_IN a_DT worse_JJR outcome_NN and_CC represents_VBZ a_DT prognostic_JJ marker_NN ._SENT Acute_JJ depletion_NN of_IN DHEAS_NP is_VBZ probably_RB related_VBN to_TO the_DT use_NN of_IN dopamine_NN and_CC high_JJ IL-6_JJ levels_NNS ._SENT The_DT prolonged_JJ depletion_NN of_IN DHEAS_NP might_MD reflect_VB an_DT exhausted_VBN adrenal_JJ adaptation_NN ._SENT Whether_IN DHEA_NP should_MD be_VB administered_VBN in_IN DHEAS-deficient_JJ states_NNS remains_VBZ to_TO be_VB elucidated_VBN ._SENT However_RB ,_, theoretically_RB ,_, beneficial_JJ effects_NNS on_IN immunity_NN ,_, susceptibility_NN for_IN infections_NNS and_CC well-being_NN may_MD be_VB expected_VBN ._SENT Critically_RB ill_JJ patients_NNS exhibit_VBP a_DT remarkable_JJ depletion_NN in_IN DHEAS_NP in_IN both_DT acute_JJ and_CC chronic_JJ phases_NNS ,_, suggesting_VBG an_DT exhausted_VBN adrenal_JJ adaptation_NN There_EX is_VBZ a_DT clear_JJ dissociation_NN between_IN DHEAS_NP (_( decreased_VBN )_) and_CC cortisol_NN (_( increased_VBN )_) levels_NNS in_IN critically_RB ill_JJ patients_NNS ,_, indicating_VBG a_DT disturbed_JJ balance_NN between_IN immunostimulatory_JJ and_CC immunosuppressive_JJ factors_NNS DHEAS_NP appears_VBZ to_TO be_VB a_DT prognostic_JJ marker_NN ,_, because_IN nonsurvivors_NNS of_IN septic_JJ shock_NN have_VBP extremely_RB low_JJ DHEAS_NP levels_NNS The_DT acute_JJ depletion_NN of_IN DHEAS_NP is_VBZ probably_RB related_VBN to_TO the_DT use_NN of_IN dopamine_NN and_CC the_DT high_JJ IL-6_NP levels_NNS during_IN the_DT acute_JJ phase_NN of_IN critical_JJ illness_NN The_DT prolonged_JJ depletion_NN of_IN DHEAS_NP during_IN critical_JJ illness_NN is_VBZ unexplained_JJ ,_, but_CC supports_VBZ the_DT hypothesis_NN of_IN an_DT exhausted_VBN neuroendocrine_NN system_NN ,_, and_CC necessitates_VBZ an_DT interventional_JJ study_NN with_IN substitution_NN doses_NNS of_IN DHEA_NP ,_, considering_VBG the_DT expected_VBN beneficial_JJ effects_NNS on_IN immunity_NN and_CC well-being_NN None_NN declared_VBD ._SENT ACTH_NN =_SYM adrenocorticotrophic_JJ hormone_NN ;_: APACHE_NP =_SYM Acute_JJ Physiology_NP and_CC Chronic_NP Health_NP Evaluation_NP ;_: DHEA(S)_NP =_SYM dehydroepiandrosterone_NN (_( sulphate_NN )_) ;_: HPA_NP =_SYM hypothalamic_JJ --_: pituitary_NN --_: adrenal_NN ;_: IL_NP =_SYM interleukin_NN ;_: TNF_NP =_SYM tumour_NN necrosis_NN factor_NN ._SENT 